A study to evaluate the safety of Nivolumab in elderly patients with previously treated non-small cell lung cancer - A study to evaluate the safety of Nivolumab in elderly patients with previously treated non-small cell lung cancer

Hiroshima University Hospital0 个研究点目标入组 30 人开始时间: 2016年2月10日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Subjects with interstitial lung disease which is detected by chest X-ray 3)Subjects with previous malignancies are excluded unless a complete remission was achieved at least 5 years prior to study entry. 4)Uncontrolled intercurrent illness including symptomatic cardiac arrhythmia, or diabetes, Intestinal obstruction. 5)known or suspected autoimmune disease, or receiving continuous systemic corticosteroid or immunosuppressant treatment. 6)Subjects with symptomatic CNS metastases or symptomatic carcinomatous meningitis. Subjects with asymptomatic CNS metastases, and subjects after 4 weeks from whole brain radiation therapy or 2 weeks from stereotactic brain radiation therapy can be included. 7)Radiation therapy within 4 weeks of the first dose of Nivolumab. 8)Subjects with known infection with HIV or AIDS . Positive test for hepatitis B virus antigen or hepatitis C virus indicating acute or chronic infection. 9)Prior therapy with antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways 10)Dementia or psychological disorder difficult to participate in this clinical study.

发起方